Table 1.
Mitochondria-targeted therapeutics.
| Therapeutics | Action mechanisms | Experimental model | PMID |
|---|---|---|---|
| Targeting mitochondrial energy metabolism | |||
| CPTI | Promotes FAO | IRI-AKI | 10751229 |
| AICAR | Regulates the AMPK pathway |
22324445, 25607838 |
|
| PDH/CS/AKGDH | Promotes TCA/oxidative phosphorylation |
31900386, 34158150, 35355864 |
|
| Complex I/Complex II | |||
| Glutamine | 30127395 | ||
| Targeting mitophagy | |||
| HIF-1α-BNIP3 | Mitophagy | IRI-AKI | 32829253 |
| PINK-PRKN/PARK2 | 29172924 | ||
| Drp1 | 29704468 | ||
| Fundc1 | 31901590 | ||
| UMI-77 | Renal fibrosis | 35524750 | |
| Tarteting ROS | |||
| IDH2 | Promotes ROS clearance | IRI-AKI | 27821630 |
| BI1 | Inhibits ROS production | 31903127 | |
| MitoQ | Inhibits ROS production | 25965144 | |
| Tarteting mitochondrial fusion and fission | |||
| Mdivi-1 | Inhibits mitochondrial fission | IRI-AKI | 29084809 |
| P110 | Inhibits mitochondrial fission |
30981733, 23239023 |
|
| TQ | Promotes mitochondrial fussion |
21718287, 33165700 |
|
| Other therapies targeting mitochondria | |||
| SS-31 | Increases ATP and reduces ROS | IRI-AKI | 21546574 |
| FGF2 | Alleviates mitochondrial damage | 32266254 | |